73 citations
,
October 2003 in “Journal of Pharmacology and Experimental Therapeutics” This study found that hair depigmentation in mice and humans can be a dynamic indicator of KIT inhibition by the drug SU11248, correlating with treatment periods.
4 citations
,
May 2024 in “Experimental Dermatology” This study reviews the role of the KIT ligand and receptor pathway in managing melanocyte and mast cell-related skin diseases, examining how its regulation can lead to potential therapies for conditions like vitiligo, melanoma, and mastocytosis. Results are not reported.
2 citations
,
September 2009 in “Pigment Cell & Melanoma Research” This study found that non-cutaneous melanocytes in mice are less sensitive to Kit signaling compared to cutaneous melanocytes, showing dependence on ET3 and HGF signaling.
1 citations
,
August 2015 in “Experimental Dermatology” This review discusses the roles of KIT and mast cells in skin physiology and pathology using different genetic models and reports no new clinical results; the authors suggest further exploration of KIT deficiency.
April 2023 in “Journal of Investigative Dermatology” In this study, topical inhibition of casein kinase 1 in mice was found to enhance melanocyte precursor migration and eumelanin production, suggesting potential applications for treating vitiligo and graying hair through KitL/c-Kit signaling pathway activation.